Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > keep the enthusiasm in check

<< Previous

Bullboard Posts

Next >>

Comment by westcoast1000on Mar 27, 2023 4:10pm

121 Views

Post# 35363187

RE:RE:keep the enthusiasm in check

Our virus may not be powerful ennough to kill enough cancer to be effective on its own. But it is very good in a LOT of indications and with a lot of other I/O agents by engaging the immune system. That more than makes up for the inability to work as a monotherapy.

<< Previous

Bullboard Posts

Next >>

Stockhouse DealRoom opens new Australian opportunities